CA3023243C - Pharmaceutical ophthalmic compositions and methods for fabricating thereof - Google Patents

Pharmaceutical ophthalmic compositions and methods for fabricating thereof Download PDF

Info

Publication number: CA3023243C
Authority: CA; Canada
Prior art keywords: pharmaceutical composition; surgery; injection; delivery; composition
Prior art date: 2016-05-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA3023243A

Other languages

English (en)

French (fr)

Other versions

CA3023243A1 (en

Inventor

William Wiley

Richard Dilzer

Dennis Elias Saadeh

Jeffrey T. Liegner

John Scott Karolchyk

Bernard Covalesky

Kallan Peters

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Harrow IP LLC

Original Assignee

Harrow IP LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-06

Filing date

2017-05-03

Publication date

2020-01-21

2016-05-06 Priority claimed from US15/148,574 external-priority patent/US20160243031A1/en

2016-06-10 Priority claimed from US15/178,812 external-priority patent/US20160279055A1/en

2017-05-03 Application filed by Harrow IP LLC filed Critical Harrow IP LLC

2017-11-09 Publication of CA3023243A1 publication Critical patent/CA3023243A1/en

2020-01-21 Application granted granted Critical

2020-01-21 Publication of CA3023243C publication Critical patent/CA3023243C/en

Status Expired - Fee Related legal-status Critical Current

2037-05-03 Anticipated expiration legal-status Critical

Links

239000000203 mixture Substances 0.000 title claims abstract description 61
238000000034 method Methods 0.000 title abstract description 29
FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims abstract description 22
229960003702 moxifloxacin Drugs 0.000 claims abstract description 21
239000002904 solvent Substances 0.000 claims abstract description 21
239000003242 anti bacterial agent Substances 0.000 claims abstract description 18
230000003381 solubilizing effect Effects 0.000 claims abstract description 18
239000000375 suspending agent Substances 0.000 claims abstract description 15
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims abstract description 12
229960005205 prednisolone Drugs 0.000 claims abstract description 11
229920001451 polypropylene glycol Polymers 0.000 claims abstract description 10
229920001400 block copolymer Polymers 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 62
238000001356 surgical procedure Methods 0.000 claims description 42
238000002347 injection Methods 0.000 claims description 40
239000007924 injection Substances 0.000 claims description 40
239000003246 corticosteroid Substances 0.000 claims description 22
239000000725 suspension Substances 0.000 claims description 21
239000000126 substance Substances 0.000 claims description 18
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 14
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 13
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 13
239000002245 particle Substances 0.000 claims description 13
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
229920000053 polysorbate 80 Polymers 0.000 claims description 13
239000002612 dispersion medium Substances 0.000 claims description 12
-1 corticol Chemical compound 0.000 claims description 11
239000003889 eye drop Substances 0.000 claims description 10
229940012356 eye drops Drugs 0.000 claims description 10
ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
108010059993 Vancomycin Proteins 0.000 claims description 8
229960003655 bromfenac Drugs 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 8
206010058202 Cystoid macular oedema Diseases 0.000 claims description 7
206010061218 Inflammation Diseases 0.000 claims description 7
208000001344 Macular Edema Diseases 0.000 claims description 7
201000010206 cystoid macular edema Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
230000004054 inflammatory process Effects 0.000 claims description 7
230000007170 pathology Effects 0.000 claims description 7
229960004618 prednisone Drugs 0.000 claims description 7
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 7
229960003165 vancomycin Drugs 0.000 claims description 7
150000001241 acetals Chemical class 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
239000003910 polypeptide antibiotic agent Substances 0.000 claims description 6
WVPSKSLAZQPAKQ-SOSAQKQKSA-N trovafloxacin Chemical compound C([C@H]1C([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-SOSAQKQKSA-N 0.000 claims description 6
229920002678 cellulose Polymers 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 5
150000002148 esters Chemical class 0.000 claims description 5
229960001810 meprednisone Drugs 0.000 claims description 5
PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 5
229920000058 polyacrylate Polymers 0.000 claims description 5
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 5
150000002170 ethers Chemical class 0.000 claims description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
229920001213 Polysorbate 20 Polymers 0.000 claims description 3
239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
239000006196 drop Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
206010014801 endophthalmitis Diseases 0.000 claims description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
235000010981 methylcellulose Nutrition 0.000 claims description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 3
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 2
XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 2
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
229930182566 Gentamicin Natural products 0.000 claims description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 2
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims description 2
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 claims description 2
108010093965 Polymyxin B Proteins 0.000 claims description 2
KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 claims description 2
108010053950 Teicoplanin Proteins 0.000 claims description 2
229960004420 aceclofenac Drugs 0.000 claims description 2
229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
229960002478 aldosterone Drugs 0.000 claims description 2
229960004821 amikacin Drugs 0.000 claims description 2
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
229960004436 budesonide Drugs 0.000 claims description 2
229960001668 cefuroxime Drugs 0.000 claims description 2
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
229960000590 celecoxib Drugs 0.000 claims description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 2
229960001209 clonixin Drugs 0.000 claims description 2
CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 claims description 2
229960004544 cortisone Drugs 0.000 claims description 2
238000004132 cross linking Methods 0.000 claims description 2
108010040131 decaplanin Proteins 0.000 claims description 2
SJSZMXQSCZCGFO-UHFFFAOYSA-N decaplanin Chemical compound C=1C2=CC=C(O)C=1C1=C(O)C=C(O)C=C1C(C(O)=O)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(C)O4)O)=CC2=CC=3OC(C=C2)=CC=C2C1OC1CC(C)(N)C(O)C(C)O1 SJSZMXQSCZCGFO-UHFFFAOYSA-N 0.000 claims description 2
229960004486 desoxycorticosterone acetate Drugs 0.000 claims description 2
229960003428 dexibuprofen Drugs 0.000 claims description 2
HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims description 2
229960002783 dexketoprofen Drugs 0.000 claims description 2
DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 claims description 2
229960001259 diclofenac Drugs 0.000 claims description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
229960000616 diflunisal Drugs 0.000 claims description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 2
229960001850 droxicam Drugs 0.000 claims description 2
OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 claims description 2
229960005293 etodolac Drugs 0.000 claims description 2
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 2
229960004945 etoricoxib Drugs 0.000 claims description 2
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims description 2
229960001419 fenoprofen Drugs 0.000 claims description 2
229960002524 firocoxib Drugs 0.000 claims description 2
FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 claims description 2
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims description 2
229960004369 flufenamic acid Drugs 0.000 claims description 2
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 2
229960002390 flurbiprofen Drugs 0.000 claims description 2
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
229960003923 gatifloxacin Drugs 0.000 claims description 2
229960002518 gentamicin Drugs 0.000 claims description 2
229960001680 ibuprofen Drugs 0.000 claims description 2
238000011065 in-situ storage Methods 0.000 claims description 2
229960000905 indomethacin Drugs 0.000 claims description 2
229950002252 isoxicam Drugs 0.000 claims description 2
YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 claims description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
229960000991 ketoprofen Drugs 0.000 claims description 2
229960004752 ketorolac Drugs 0.000 claims description 2
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
229950003488 licofelone Drugs 0.000 claims description 2
UAWXGRJVZSAUSZ-UHFFFAOYSA-N licofelone Chemical compound OC(=O)CC=1N2CC(C)(C)CC2=C(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 UAWXGRJVZSAUSZ-UHFFFAOYSA-N 0.000 claims description 2
229960002373 loxoprofen Drugs 0.000 claims description 2
BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims description 2
229960003803 meclofenamic acid Drugs 0.000 claims description 2
229960003464 mefenamic acid Drugs 0.000 claims description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 2
229960001929 meloxicam Drugs 0.000 claims description 2
229960004270 nabumetone Drugs 0.000 claims description 2
229960002009 naproxen Drugs 0.000 claims description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
229960001002 nepafenac Drugs 0.000 claims description 2
QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims description 2
229960000965 nimesulide Drugs 0.000 claims description 2
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims description 2
229960002739 oxaprozin Drugs 0.000 claims description 2
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
229960004662 parecoxib Drugs 0.000 claims description 2
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims description 2
229960002702 piroxicam Drugs 0.000 claims description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
229960003548 polymyxin b sulfate Drugs 0.000 claims description 2
229950003551 ramoplanin Drugs 0.000 claims description 2
108010076689 ramoplanin Proteins 0.000 claims description 2
229960000371 rofecoxib Drugs 0.000 claims description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
229960004889 salicylic acid Drugs 0.000 claims description 2
229960000953 salsalate Drugs 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
229960000894 sulindac Drugs 0.000 claims description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
229960001608 teicoplanin Drugs 0.000 claims description 2
229960005240 telavancin Drugs 0.000 claims description 2
108010089019 telavancin Proteins 0.000 claims description 2
ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims description 2
229960002905 tolfenamic acid Drugs 0.000 claims description 2
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims description 2
229960001017 tolmetin Drugs 0.000 claims description 2
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 2
229960001082 trimethoprim Drugs 0.000 claims description 2
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 2
229960002004 valdecoxib Drugs 0.000 claims description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 2
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims 1
229960002202 lornoxicam Drugs 0.000 claims 1
OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims 1
229960000994 lumiracoxib Drugs 0.000 claims 1
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims 1
229960000707 tobramycin Drugs 0.000 claims 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
239000002260 anti-inflammatory agent Substances 0.000 abstract description 7
229940121363 anti-inflammatory agent Drugs 0.000 abstract description 7
238000009472 formulation Methods 0.000 description 21
239000000047 product Substances 0.000 description 21
150000001875 compounds Chemical class 0.000 description 20
239000000243 solution Substances 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 9
239000003814 drug Substances 0.000 description 9
229940079593 drug Drugs 0.000 description 9
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 9
229960002117 triamcinolone acetonide Drugs 0.000 description 9
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 8
229940068968 polysorbate 80 Drugs 0.000 description 8
210000001508 eye Anatomy 0.000 description 7
229920001992 poloxamer 407 Polymers 0.000 description 7
229940044476 poloxamer 407 Drugs 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 6
229960001334 corticosteroids Drugs 0.000 description 6
150000004677 hydrates Chemical class 0.000 description 6
IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 6
229960005112 moxifloxacin hydrochloride Drugs 0.000 description 6
230000002980 postoperative effect Effects 0.000 description 6
239000012453 solvate Substances 0.000 description 6
239000008227 sterile water for injection Substances 0.000 description 6
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 6
LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 5
229960002800 prednisolone acetate Drugs 0.000 description 5
238000009987 spinning Methods 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
208000002177 Cataract Diseases 0.000 description 4
230000000844 anti-bacterial effect Effects 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
229940095629 edetate calcium disodium Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
229950008882 polysorbate Drugs 0.000 description 4
230000008569 process Effects 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
238000003756 stirring Methods 0.000 description 4
229960005294 triamcinolone Drugs 0.000 description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
210000002159 anterior chamber Anatomy 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229940124307 fluoroquinolone Drugs 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
230000036512 infertility Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
239000004327 boric acid Substances 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940113960 edetate calcium Drugs 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
238000005189 flocculation Methods 0.000 description 2
230000016615 flocculation Effects 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
239000013029 homogenous suspension Substances 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
201000005111 ocular hyperemia Diseases 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229960000502 poloxamer Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
RLGNNNSZZAWLAY-UHFFFAOYSA-N 2-(2,3-dimethoxy-4-methylsulfanylphenyl)ethanamine Chemical compound COC1=C(CCN)C=CC(SC)=C1OC RLGNNNSZZAWLAY-UHFFFAOYSA-N 0.000 description 1
RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
SKZIMSDWAIZNDD-WJMOHVQJSA-N 7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrate;hydrochloride Chemical compound O.Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 SKZIMSDWAIZNDD-WJMOHVQJSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
206010063659 Aversion Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010011033 Corneal oedema Diseases 0.000 description 1
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
208000034423 Delivery Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010067268 Post procedural infection Diseases 0.000 description 1
206010036346 Posterior capsule opacification Diseases 0.000 description 1
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229940062316 avelox Drugs 0.000 description 1
229960004648 betamethasone acetate Drugs 0.000 description 1
AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229960002645 boric acid Drugs 0.000 description 1
229960002716 bromfenac sodium Drugs 0.000 description 1
HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004240 ciliary body Anatomy 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
201000004778 corneal edema Diseases 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
150000001884 corticosterones Chemical class 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
229960001347 fluocinolone acetonide Drugs 0.000 description 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
229960001048 fluorometholone Drugs 0.000 description 1
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
150000008040 ionic compounds Chemical class 0.000 description 1
239000013010 irrigating solution Substances 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229940063199 kenalog Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000012875 nonionic emulsifier Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
238000006068 polycondensation reaction Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
OSWKQSQWSQSPQH-GNFRAIDCSA-N tiamcinoloni furetonidum Chemical compound C1=CC=C2OC(C(=O)OCC(=O)[C@]34[C@@]5(C)C[C@H](O)[C@]6(F)[C@@]7(C)C=CC(=O)C=C7CC[C@H]6[C@@H]5C[C@H]3OC(O4)(C)C)=CC2=C1 OSWKQSQWSQSPQH-GNFRAIDCSA-N 0.000 description 1
210000001585 trabecular meshwork Anatomy 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
229950006782 triamcinolone benetonide Drugs 0.000 description 1
GUYPYYARYIIWJZ-CYEPYHPTSA-N triamcinolone benetonide Chemical compound O=C([C@]12[C@H](OC(C)(C)O1)C[C@@H]1[C@@]2(C[C@H](O)[C@]2(F)[C@@]3(C)C=CC(=O)C=C3CC[C@H]21)C)COC(=O)C(C)CNC(=O)C1=CC=CC=C1 GUYPYYARYIIWJZ-CYEPYHPTSA-N 0.000 description 1
229960004320 triamcinolone diacetate Drugs 0.000 description 1
229950002113 triamcinolone furetonide Drugs 0.000 description 1
229960004221 triamcinolone hexacetonide Drugs 0.000 description 1
229940072335 vancocin Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Dispersion Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA3023243A 2016-05-06 2017-05-03 Pharmaceutical ophthalmic compositions and methods for fabricating thereof Expired - Fee Related CA3023243C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US15/148,574		2016-05-06
US15/148,574 US20160243031A1 (en)	2013-07-22	2016-05-06	Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US15/178,812 US20160279055A1 (en)	2013-07-22	2016-06-10	Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US15/178,812		2016-06-10
PCT/US2017/030772 WO2017192675A1 (en)	2016-05-06	2017-05-03	Pharmaceutical ophthalmic compositions and methods for fabricating thereof

Publications (2)

Publication Number	Publication Date
CA3023243A1 CA3023243A1 (en)	2017-11-09
CA3023243C true CA3023243C (en)	2020-01-21

Family

ID=60203416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3023243A Expired - Fee Related CA3023243C (en)	2016-05-06	2017-05-03	Pharmaceutical ophthalmic compositions and methods for fabricating thereof

Country Status (6)

Country	Link
EP (1)	EP3452033A4 (de)
JP (1)	JP6694525B2 (de)
KR (2)	KR20190109604A (de)
AU (1)	AU2017260327B2 (de)
CA (1)	CA3023243C (de)
WO (1)	WO2017192675A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2846935C1 (ru) *	2024-08-15	2025-09-19	федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации	Способ хирургического лечения хронического "мешковидного" эндофтальмита после катарактальной хирургии

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3074326A1 (en) *	2017-09-01	2019-03-07	Murray & Poole Enterprises, Ltd.	Methods and compositions for the treatment of ophthalmic conditions
US11071724B2 (en)	2019-05-17	2021-07-27	Ocular Science, Inc.	Compositions and methods for treating presbyopia
WO2021252054A1 (en) *	2020-06-10	2021-12-16	Ocular Science, Inc.	Compositions and uses in method for post-operative ocular care
EP4238552A1 (de) *	2020-10-29	2023-09-06	Taejoon Pharmaceutical Co., Ltd.	Ophthalmische zusammensetzung
WO2022156371A1 (zh) *	2021-01-22	2022-07-28	成都瑞沐生物医药科技有限公司	一种眼用制剂的载体或辅料及其制备方法和应用
US12594351B2 (en)	2021-08-04	2026-04-07	Harrow Ip Llc	Methods for increasing shelf-life of ophthalmic pharmaceutical compositions
WO2025259121A1 (en) *	2024-06-12	2025-12-18	Aft Pharmaceuticals Ltd	Vancomycin eye drops

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6716830B2 (en) *	1998-09-30	2004-04-06	Alcon, Inc.	Ophthalmic antibiotic compositions containing moxifloxacin
JP2003510263A (ja) *	1999-09-24	2003-03-18	アルコン，インコーポレイテッド	シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
EP1596823A2 (de) *	2003-02-21	2005-11-23	Sun Pharmaceuticals Industries Ltd.	Stabile ophthalmische zusammensetzung
US20050085446A1 (en) *	2003-04-14	2005-04-21	Babu M.K. M.	Fluoroquinolone formulations and methods of making and using the same
US7109247B2 (en) *	2003-05-30	2006-09-19	3M Innovative Properties Company	Stabilized particle dispersions containing nanoparticles
US7799331B2 (en) *	2005-08-04	2010-09-21	Taro Pharmaceutical North America, Inc.	Oral suspension of prednisolone acetate
BRPI0819908A2 (pt) *	2007-11-27	2015-05-19	Alcon Res Ltd	Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona
UA119324C2 (uk) *	2013-04-02	2019-06-10	Теміс Медікер Лімітед	Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
US20150164882A1 (en) *	2013-07-22	2015-06-18	Imprimis Pharmaceuticals, Inc.	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150025511A1 (en) *	2013-07-22	2015-01-22	Imprimis Pharmaceuticals, Inc.	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en) *	2014-08-15	2016-04-14	Imprimis Pharmaceuticals, Inc.	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
MX383077B (es) *	2013-07-22	2025-03-13	Novel Drug Solutions Llc	Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.

2017
- 2017-05-03 CA CA3023243A patent/CA3023243C/en not_active Expired - Fee Related
- 2017-05-03 AU AU2017260327A patent/AU2017260327B2/en not_active Ceased
- 2017-05-03 KR KR1020197027514A patent/KR20190109604A/ko not_active Ceased
- 2017-05-03 WO PCT/US2017/030772 patent/WO2017192675A1/en not_active Ceased
- 2017-05-03 EP EP17793224.1A patent/EP3452033A4/de not_active Withdrawn
- 2017-05-03 KR KR1020187033036A patent/KR20180126087A/ko not_active Ceased
- 2017-05-03 JP JP2018558268A patent/JP6694525B2/ja active Active

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2846935C1 (ru) *	2024-08-15	2025-09-19	федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации	Способ хирургического лечения хронического "мешковидного" эндофтальмита после катарактальной хирургии

Also Published As

Publication number	Publication date
KR20190109604A (ko)	2019-09-25
JP6694525B2 (ja)	2020-05-13
WO2017192675A1 (en)	2017-11-09
CA3023243A1 (en)	2017-11-09
AU2017260327B2 (en)	2018-12-20
JP2019514975A (ja)	2019-06-06
EP3452033A4 (de)	2020-02-12
EP3452033A1 (de)	2019-03-13
AU2017260327A1 (en)	2018-11-29
KR20180126087A (ko)	2018-11-26

Legal Events

Date	Code	Title	Description
2019-04-23	EEER	Examination request	Effective date: 20190404
2023-12-16	MKLA	Lapsed	Effective date: 20220503

Publication	Publication Date	Title
US11684570B2 (en)	2023-06-27	Pharmaceutical ophthalmic compositions
US11510916B2 (en)	2022-11-29	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP7362870B2 (ja)	2023-10-17	抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
CA3023243C (en)	2020-01-21	Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20160243031A1 (en)	2016-08-25	Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20160175323A1 (en)	2016-06-23	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160184323A1 (en)	2016-06-30	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en)	2016-04-14	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20190105320A1 (en)	2019-04-11	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150129457A1 (en)	2015-05-14	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20190111045A1 (en)	2019-04-18	Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US9814673B2 (en)	2017-11-14	Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
WO2020117497A1 (en)	2020-06-11	Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
EP4260844B1 (de)	2026-03-18	Ophthalmologische zusammensetzungen mit poloxamer
US20160045432A1 (en)	2016-02-18	Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
WO2016024956A1 (en)	2016-02-18	Intraocular lens comprising fluoroquinolone and a corticosteroid and methods for fabricating thereof
HK1223824B (en)	2021-05-14	Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent

CA3023243C - Pharmaceutical ophthalmic compositions and methods for fabricating thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (2)

Family

ID=60203416

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (7)

Family Cites Families (12)

Cited By (1)

Also Published As

Similar Documents

Legal Events